Cargando…

2144. Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for Enterobacteriaceae and Pseudomonas aeruginosa Directly from Positive Blood Culture on the Accelerate Pheno™ System

BACKGROUND: The Clinical and Laboratory Standards Institute (CLSI) updated fluoroquinolone breakpoints in 2019 in response to evolving resistance and new outcome data. The performance of updated antimicrobial susceptibility testing (AST) algorithms for ciprofloxacin with the 2019 breakpoints for Ent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shamsheyeva, Alena, Oppermann, Niels, Taku, Aimee, Ndobegang, Anyangatia, Gamage, Dulini, Chantell, Christina, Humphries, Romney
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809880/ http://dx.doi.org/10.1093/ofid/ofz360.1824

Ejemplares similares

Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates
por: Sikorski, Aaron, et al.
Publicado: (2021)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
por: Park, Ga Eun, et al.
Publicado: (2021)

Effective implementation of the Accelerate Pheno™ system for positive blood cultures
por: Humphries, Romney, et al.
Publicado: (2019)

673. Updated CLSI Ciprofloxacin Breakpoints from a Multicenter Assessment for Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2020)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

CLSI announces availability of new CLSI microbiology documents
Publicado: (2007)

Vacuum gaps in pulsars and PSR J2144-3933
por: Gil, J, et al.
Publicado: (2001)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

667. Multicenter Assessment of Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using Updated CLSI Levofloxacin Breakpoints on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2020)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

2144. Vital Signs Are Vital in Identifying High-Risk Postoperative Patients
por: Bhaimia, Eric, et al.
Publicado: (2018)

2144. Duration of perioperative antibiotic prophylaxis in ventriculoperitoneal shunt surgery in children
por: Tada, Ayumi, et al.
Publicado: (2022)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
por: Kuti, Joseph L, et al.
Publicado: (2018)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

Pheno 2019
Publicado: (2019)

Reproducibility of Ceftolozane/Tazobactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-negative MIC Panels
por: Harrington, Amanda, et al.
Publicado: (2017)

Reproducibility of Ceftazidime/Avibactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Humphries, Romney, et al.
Publicado: (2017)

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
por: Yang, Xianggui, et al.
Publicado: (2019)

Pheno 2005 Symposium
Publicado: (2005)

PHENO 2001 Symposium
Publicado: (2001)

Future Perspectives at HL-LHC Prospects for Pheno26, Pheno31, and beyond
por: Jeanty, Laura
Publicado: (2021)

Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints
por: Simner, Patricia J, et al.
Publicado: (2022)

Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution
por: Robledo-Leal, Efrén, et al.
Publicado: (2012)

1446. The Impact of Enterobacteriaceae Isolate Breakpoints on Prescriber Treatment Choices for Discordant Pattern Urinary Tract Infections
por: Lee, Philip, et al.
Publicado: (2019)

PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
por: Susic, G, et al.
Publicado: (2013)

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999
por: Livermore, David M., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_ln5ufqtsqmic689ams245q9gg8